ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026
Reinstating Niche Failure in Diabetic Cranial Defects via Chronotaxic Signal-Amplifying Fluidic Biomimetic Hydrogel.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Hydrogel Implementing Drug Delivery in Cranial Bone Tissue Engineering.Journal of functional biomaterials · 2026Review
- Curcumin-based smart responsive hydrogels: A controlled release system for bone defect regeneration.Regenerative therapy · 2026Review
- Reinstating Niche Failure in Diabetic Cranial Defects via Chronotaxic Signal-Amplifying Fluidic Biomimetic Hydrogel.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Cranial stem cell niches (SCNs) are intrinsically scarce and hypoactive, and, exacerbated by chronic inflammation in diabetes, lead to niche failure and regenerative deficit after injury. Herein, an in situ moldable fluidic biomimetic niche (GelSSO/PDA@SDF) is developed as a chronotaxic signal amplifier to enhance SCN abundance and activity, aiming to restore autonomous regeneration. This biomimetic niche integrates PDA@SDF nanoparticles and a GelSSO hydrogel precursor, synthesized via dopamine self-polymerization/protein coupling and sequential methacrylation/sequence-specific oligodeoxynucleotide (SSO) grafting, respectively. Photocrosslinked GelSSO/PDA@SDF can preferentially and sustainably release PDA@SDF nanoparticles to trigger early-phase signal amplification, characterized by SDF-1α/CXCR4-mediated recruitment of endothelial and mesenchymal progenitors, vascular niche activation driving AKT-dependent angiogenesis, and suppressed M1 macrophage dominance. Progressive hydrogel degradation initiates the secondary signal amplification phase, in which prolonged SSO release creates a transcriptionally active osteogenic niche for MAPK/ERK-induced osteogenesis. In vivo, the in situ structured GelSSO/PDA@SDF conformed to defect geometry, promoting the early establishment of an immunologically favorable, progenitor-enriched niche through local immunomodulation and endogenous cell homing, followed by successive activation of vascular and osteogenic niches, ultimately achieving diabetic cranial vascularized bone regeneration. Thus, this chronotaxic signal-amplifying biomimetic niche offers a versatile strategy for restoring autonomous regeneration in the diabetic cranium and other poorly regenerative tissues.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.